Members Trust Co Increases Holdings in Pfizer Inc. (NYSE:PFE)

Members Trust Co grew its position in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the fourth quarter, Holdings Channel reports. The fund owned 23,162 shares of the biopharmaceutical company’s stock after purchasing an additional 500 shares during the period. Members Trust Co’s holdings in Pfizer were worth $667,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Worth Asset Management LLC purchased a new position in shares of Pfizer during the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer in the 3rd quarter worth approximately $30,000. Sanctuary Wealth Management L.L.C. purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $50,000. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer in the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC grew its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.04 during midday trading on Monday, hitting $25.90. 35,623,531 shares of the stock traded hands, compared to its average volume of 42,737,133. The firm has a 50-day moving average of $27.28 and a two-hundred day moving average of $28.88. The firm has a market capitalization of $146.66 billion, a P/E ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a one year low of $25.61 and a one year high of $41.33.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.14 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on PFE shares. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.